We recently compiled a list of the 10 Best Biotech Stocks to Buy According to Analysts. Celldex Therapeutics, Inc.

Flash talks on barzolvolimab clinical program in CSU and Cold Urticaria ---- Late-breaking poster presentation on CDX-622 --HAMPTON, N.J., ...

HAMPTON, N.J., June 15, 2020 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (“Celldex” or the “Company”) (Nasdaq: CLDX), today announced the pricing of its previously announced underwritten public ...

Celldex Therapeutics (CLDX) has attracted fresh attention after a recent move in its share price, with the stock closing at US$31.27 and showing mixed short term performance over the past week and ...

Celldex Therapeutics (NASDAQ: CLDX) is in a much different place than it was one year ago. The biotech continues to feel the repercussions from the failure of glembatumumab vedotin (glemba) in the ...

(Reuters) - New data from a midstage trial show that Celldex Therapeutics Inc's experimental brain cancer vaccine, combined with standard therapy, continues to improve chances of survival for patients ...

What happened with Celldex this quarter? The nice increase in revenue during the first quarter stemmed primarily from Celldex's clinical-trial collaboration with Bristol-Myers Squibb. Additional ...

In the last three months, 7 analysts have published ratings on Celldex Therapeutics (NASDAQ:CLDX), offering a diverse range of perspectives from bullish to bearish. The table below summarizes their ...

Celldex to buy CuraGen for $94.5 mln in stock Deal expected to close in Q3 Deal to add to Celldex's immunotherapy platform May 29 (Reuters) - Celldex Therapeutics Inc said it agreed to acquire CuraGen ...

LB Pharmaceuticals and Celldex have separately stepped up their respective launch preparations by appointing new chief commercial officers, according to a pair of announcements this week. New ...

Adding an experimental Celldex Therapeutics Inc vaccine that enlists the immune system to fight cancer to standard therapy helped patients with the deadliest type of brain cancer live longer, ...

For Celldex Therapeutics (CLDX 1.28%), 2016 was a horrible year. The biotech stock dropped 77% after experimental vaccine Rintega flopped in a late-stage clinical study. Celldex entered 2017 with ...